Desk›Healthcare› Novartis India Ltd
Novartis India Ltd
BSE 500672 · NSE NOVARTIND · ISIN INE234A01025 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,494.10
+0.28%
BSE close, 28 August 2026
₹3,689.05 cr
2.5 cr shares · Micro cap
₹1,055.58 cr
as published
37.7× · 5.06×
EPS ₹39.60 · BV ₹295.28
354.33 / 93.18
₹ cr, as filed
44
13 selected · 30%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -15.9% |
|---|---|
| Against 52-week low | +99.2% |
| Day change | +0.28% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹39.60 |
|---|---|
| Price / earnings | 37.73× |
| Price / book | 5.06× |
| Book value — derived, price ÷ P/B | ₹295.28 |
| Return on equity | 13.41% |
| Operating margin | 42.05% |
| Net margin | 31.03% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 13.41%
- ROE as published
- 13.41%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 103.81 | 32.21 | 13.05 | 42.05% | 31.03% |
| Mar-26 · Q | 90.55 | 25.25 | 10.23 | 33.83% | 27.89% |
| FY25-26 | 354.33 | 93.18 | 37.74 | 37.50% | 26.30% |
Quarter on quarter
- Revenue, quarter on quarter
- +14.6%
- Net profit, quarter on quarter
- +27.6%
- Operating margin, quarter on quarter
- +822 bps
Disclosure profile 44 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Fundraising | 2 |
| KMP | 2 |
| Change in Management | 1 |
| Credit Rating | 1 |
| Investor Presentation | 1 |
| Name Change | 1 |
| Press Release | 1 |
| Resignation | 1 |
| Results | 1 |
| Selected sub-total | 13 |
| Procedural | |
| General | 10 |
| AGM / EGM | 4 |
| Analyst / Investor Meet | 3 |
| Newspaper Publication | 3 |
| Outcome | 3 |
| Board Meeting | 2 |
| Annual Report | 1 |
| BRSR | 1 |
| Charter Amendment | 1 |
| Other Update | 1 |
| SAST | 1 |
| Trading Window | 1 |
| Procedural sub-total | 31 |
| Total | 44 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
44 filings · 13 selected · busiest 2026-07-29
Filing rhythm · the twelve most recent
2026-09-232026-10-08
SelectedProcedural
Filings
44 in the window · 18 earlier on record
-
8 October 2026 ·
Raising of Funds
The Board of Directors of the Company Evonile Pharma Limited (formally known as Novartis India Limited) approved the raising of funds by way of Rights Issue at their Board Meeting held ....
Company Update / Raising of Funds View filing →
-
8 October 2026 ·
Issue of Securities
The Board of Directors of Evonile Pharma Limited (formally known as Novartis India Limited) has approved the raising of funds by way of Rights Issue at their Board Meeting held today i.e. ....
Company Update / Issue of Securities View filing →
-
8 October 2026 ·
Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Held Today Dated October 08, 2026
Intimation of the Outcome of the Board Meeting held today dated October 08, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
7 October 2026 ·
Credit Rating
Intimation of the Credit Ratings assigned by CARE Ratings Limited.
Company Update / Credit Rating View filing →
-
5 October 2026 ·
Board Meeting Intimation for Consideration Of Raising Of Funds Through The Issuance Of Equity Shares Of The Company.
Novartis India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/10/2026 ,inter alia, to consider and approve the raising of funds through ....
Board Meeting / Board Meeting View filing →
-
1 October 2026 ·
Amendments to Memorandum & Articles of Association
Intimation regarding the Amendments to the Memorandum and Articles of Association of the Company
Company Update / Amendments to Memorandum & Articles of Association View filing →
-
1 October 2026 ·
Change of Company Name
Intimation of the Change of Name of Company from Novartis India Limited to Evonile Pharma Limited pursuant to the Fresh Certificate of Inc orporation dated October 01, 2026, issued by Ministry ....
Company Update / Change of Name View filing →
-
30 September 2026 ·
Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Novartis India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Board Meeting / Board Meeting View filing →
-
30 September 2026 ·
Closure of Trading Window
Intimation of the closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
25 September 2026 ·
Intimation Of The Voting Results And The Scrutinizers Report For The 78Th Annual General Meeting Of The Company Held On Thursday, September 24, 2026.
Intimation of the Voting Results and the Scrutinizers Report for the 78th Annual General Meeting of the Company held on Thursday, September 24, 2026.
AGM/EGM / AGM View filing →
-
24 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Intimation of the proceedings of the 78th Annual General Meeting of Novartis India Limited held on September 24, 2026.
AGM/EGM / AGM View filing →
-
23 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation is hereby given that the Officials of the Company will be participating in the Conference / Meeting scheduled on Emerging India CEO Forum by Nuvama on Monday, September 28, 2026.
Company Update / Analyst / Investor Meet View filing →
-
21 September 2026 ·
Intimation Regarding The Newspaper Publication Made Regarding The Corrigendum Filed Dated September 18, 2026, For The Notice Of 78Th Annual General Meeting
Intimation regarding the newspaper publication made regarding the Corrigendum filed dated September 18, 2026, for the Notice of 78th Annual General Meeting
Company Update / General View filing →
-
18 September 2026 ·
Corrigendum To The Notice Of 78Th Annual General Meeting
Corrigendum to the Notice of 78th Annual General Meeting dated August 27, 2026
AGM/EGM / AGM View filing →
-
15 September 2026 ·
Analyst / Investor Meet - Outcome
Transcript of the Analysts / Institutional Investors Call held on September 11, 2026.
Company Update / Analyst / Investor Meet View filing →
-
11 September 2026 ·
Investor Presentation
With reference to the intimation of the Investor / Analyst Call dated September 08, 2026, please find attached herewith the Investor Presentation in relation to the same.
Company Update / Investor Presentation View filing →
-
9 September 2026 ·
Intimation Pursuant To Regulation 36(1)(B) Of SEBI LODR Regulations
Intimation pursuant to Regulation 36(1)(b) of the SEBI LODR Regulations to non-email shareholders regarding the Weblink and Annual Report for FY 2025-26 by the way of physical dispatch of letters.
Company Update / General View filing →
-
8 September 2026 ·
Analyst / Investor Meet - Intimation
Intimation regarding the Investor / Analyst Call scheduled to be held on Friday, September 11, 2026, 04:00 PM IST onwards, through Physical and Virtual Mode.
Company Update / Analyst / Investor Meet View filing →
-
8 September 2026 ·
Intimation Under Reg 30 Of SEBI LODR Regarding Entering Into Exclusive Promotion And Distribution Agreement With Novartis Healthcare Private Limited
Intimation under Reg 30 of SEBI LODR regarding entering into Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited for its retina portfolio comprising ....
Company Update / General View filing →
-
7 September 2026 ·
Intimation Regarding The Acquisition Of Trademarks "Minipress" And "Minipres" From Pfizer Inc. USA And Pfizer Products Inc. USA, The Same Is Approved By The Board Of Directors Of The Company At Their Board Meeting Held Today I.E. September 07, 2026
Intimation regarding the acquisition of trademarks "Minipress" and "Minipres" registered in India and certain related intellectual property rights from Pfizer Inc. USA and Pfizer Products ....
Company Update / General View filing →
-
3 September 2026 ·
Newspaper Publication
Newspaper Publication made on September 03, 2026, in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02, 2026, regarding the Notice of the 78th ....
Company Update / Newspaper Publication View filing →
-
2 September 2026 ·
Reg. 34 (1) Annual Report.
Annual Report of Novartis India Limited for FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
2 September 2026 ·
Notice Of The 78Th Annual General Meeting Of Novartis India Limited To Be Held On Thursday, September 24, 2026, Through Video Conferencing (VC) / Other Audio Visual Means (OAVM)
Notice of the 78th Annual General Meeting of Novartis India Limited to be held on Thursday, September 24, 2026, through Video Conferencing (VC) / Other Audio Visual Means (OAVM)
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
BRSR Report of Novartis India Limited for FY 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
28 August 2026 ·
Newspaper Publication
The Intimation is submitted with BSE regarding the information provided to the Members of the Company for the 78th Annual General Meeting through Newspaper Advertisement
Company Update / Newspaper Publication View filing →
-
17 August 2026 ·
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company Held On August 17, 2026
Outcome of the meeting of the Board of Directors of the Company held on August 17, 2026
Others / Outcome without intimation View filing →
-
7 August 2026 ·
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 07, 2026
Intimation of the outcome of the Board Meeting held today i.e. August 07, 2026
Others / Outcome without intimation View filing →
-
29 July 2026 ·
Press Release / Media Release
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Press Release.
Company Update / Press Release / Media Release View filing →
-
29 July 2026 ·
Outcome Of The 247Th Meeting Of The Board Of Directors Held Today, I.E, Wednesday, July 29, 2026.
Outcome of the 247th meeting of the Board of Directors held today, i.e, Wednesday, July 29, 2026.
Company Update / General View filing →
-
29 July 2026 ·
Outcome Of The 246Th Meeting Of The Board Of Directors Held On Today I.E, Wednesday, July 29, 2026.
Outcome of the 246th Board Meeting of the Board of Directors of Novartis India Limited held today i.e, Wednesday, July 29, 2026.
Company Update / General View filing →
-
29 July 2026 ·
Resignation of Chairman
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July 29, 2026 took note of the Resignation of Mr. Christopher David Snook as ....
Company Update / Resignation of Chairman View filing →
-
29 July 2026 ·
Resignation of Director
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July 29, 2026 took note of the Resignation of the Directors of the company.
Company Update / Resignation of Director View filing →
-
29 July 2026 ·
Resignation of Chief Financial Officer (CFO)
The Board of Directors of Novartis India Limited ("the Company") at its meeting held today i.e, Wednesday, July, 26, 2026 took note of resignation of Ms. Shilpa Joshi as the Chief Financial ....
Company Update / Resignation of Chief Financial Officer (CFO) View filing →
-
29 July 2026 ·
Change In Control Of The Novartis India Limited ("The Company").
The Board of Directors of Novartis India Limited ("the Company') in its meeting today, July 29, 2026 approved the Change in Control of the Company.
Company Update / General View filing →
-
29 July 2026 ·
Cessation
The Board of Directors of Novartis India Limited ("the Company") at its Meeting held today, July 29, 2026 approved the Cessation of the exisiting Directors.
Company Update / Cessation View filing →
-
29 July 2026 ·
Change in Management
The Board of Directors of Novartis India Limited ("the Company") held today, i.e, Wednesday, July 29, 2026 approved the Appointment and Resignation of Directors.
Company Update / Change in Management View filing →
-
29 July 2026 ·
Disclosure In Terms Of Regulation 29(2) Of The Securities And Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) ("SAST"), 2015.
Disclosure in terms of Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations, 2015.
Company Update / General View filing →
-
29 July 2026 ·
Disclosure In Terms Of Regulation 7(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations, 2015.
Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
Company Update / General View filing →
-
29 July 2026 ·
Intimation Under Regulation 31A (10) And Other Applicable Provisions Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015, ("SEBI Listing Regulations").
Intimation under Regulation 31A (10) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").
Company Update / General View filing →
-
29 July 2026 ·
Board Meeting Outcome for Outcome Of The 245Th Meeting Of The Board Of Directors Of Novartis India Limited ("The Company") Held Today, Wednesday, July 29, 2026.
Outcome of the 245th Meeting of the Board of Directors of Novartis India Limited ("the Company") held today, Wednesday, July 29, 2026.
Others / Outcome without intimation View filing →
-
29 July 2026 ·
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for WaveRise Investments Ltd
Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 View filing →
-
24 July 2026 ·
Newspaper Publication
Intimation of Newspaper Advertisement by Novartis India Limited ("the Company") regarding the publication of Unaudited Financial Results of the Company for the Quarter ended June 30, 2026.
Company Update / Newspaper Publication View filing →
-
23 July 2026 ·
Financial Results Of Novartis India Limited For The Quarter Ended June 30, 2026.
Financial Results along with the Limited Review Report of Novartis India Limited for the quarter ended June 30, 2026.
Result / Financial Results View filing →
-
23 July 2026 ·
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited Held On Thursday, July 23, 2026.
Outcome of the meeting of the Board of Directors of Novartis India Limited held on Thursday, July, 23, 2026.
Board Meeting / Outcome of Board Meeting View filing →
RSS feed for Novartis India Ltd · the 50 most recent filings